Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient

Virology

Volumn 370, Issue 2, 2008, Pages 237-245

  Cubero, Maria ^a,b,c   Esteban, Juan Ignacio ^a,b,c   Otero, Teresa ^a   Sauleda, Silvia ^c,d   Bes, Marta ^c,d   Esteban, Rafael ^a,b,c   Guardia, Jaume ^a,b,c   Quer, Josep ^a,b,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d INSTITUT CATALÀ DE LA SALUT   (Spain)

Author keywords

HCV NS3; Inhibitor; Mutant; Patient; Resistant; Untreated

Indexed keywords

CILUPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 3 PROTEASE INHIBITOR; PROTEINASE INHIBITOR; SCH 446211; SCH 4466211; SCH 503034; UNCLASSIFIED DRUG; VX 950;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CARDIOTOXICITY; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME POLYMORPHISM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MUTAGENESIS; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS RESISTANCE;

ADULT; AMINO ACID SEQUENCE; BASE SEQUENCE; CARBAMATES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENES, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; MACROCYCLIC COMPOUNDS; MALE; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; POINT MUTATION; PROLINE; QUINOLINES; SEQUENCE HOMOLOGY, AMINO ACID; SEQUENCE HOMOLOGY, NUCLEIC ACID; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; THIAZOLES; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 36549028822     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.10.006     Document Type: Article

References (36)

1. Andre P., Kim A., Khrapko K., and Thilly W.G. Fidelity and mutational spectrum of Pfu DNA polymerase on a human mitochondrial DNA sequence. Genome Res. 7 (1997) 843-852
2. Cabot B., Martell M., Esteban J.I., Piron M., Otero T., Esteban R., Guardia J., and Gomez J. Longitudinal evaluation of the structure of replicating and circulating hepatitis C virus quasispecies in nonprogressive chronic hepatitis C patients. J. Virol. 75 (2001) 12005-12013
3. Chang M., Marquardt A.P., Wood B.L., Williams O., Cotler S.J., Taylor S.L., Carithers Jr. R.L., and Gretch D.R. In situ distribution of hepatitis C virus replicative-intermediate RNA in hepatic tissue and its correlation with liver disease. J. Virol. 74 (2000) 944-955
4. Chang M., Williams O., Mittler J., Quintanilla A., Carithers Jr. R.L., Perkins J., Corey L., and Gretch D.R. Dynamics of hepatitis C virus replication in human liver. Am. J. Pathol. 163 (2003) 433-444
5. Cline J., Braman J.C., and Hogrefe H.H. PCR fidelity of pfu DNA polymerase and other thermostable DNA polymerases. Nucleic Acids Res. 24 (1996) 3546-3551
6. Domingo, E. (1989). RNA virus evolution and the control of viral disease. In ``Progress in drug research." (Ed. Jucker Birkhauser Verlag, Ed.), Vol. 33, pp. 93-133. Vol. XXXIII. Basel.
7. Domingo E., and Holland J.J. High error rates, population equilibrium, and evolution of RNA replication systems. In: Domingo E., and Holland J.J. (Eds). RNA Genetics (1988), CRC Press, Boca Raton, Florida 3-36
8. Domingo E., and Holland J.J. Complications of RNA heterogeneity for the engineering of virus vaccines and antiviral agents. Genet. Eng. (N.Y) 14 (1992) 13-31
9. Domingo E., and Holland J.J. Mutation rates and rapid evolution of RNA viruses. In: Morse S.S. (Ed). Evolutionary Biology of Viruses (1994), Raven Press, New York 161-184
10. Duarte E.A., Novella I.S., Weaver S.C., Domingo E., Wain-Hobson S., Clarke D.K., Moya A., Elena S.F., De La Torre J.C., and Holland J.J. RNA virus quasispecies: significance for viral disease and epidemiology. Infect. Agents Dis. 3 (1994) 201-214
11. Eigen M., and Biebricher C.K. Variability of RNA genomes. Sequence space and quasispecies distribution. In: Domingo E., Holland J.J., and Ahlquist P. (Eds). RNA Genetics vol. 3 (1988), CRC Press, Inc., Boca Ratón, Florida 211-245
12. Escarmis C., Davila M., and Domingo E. Multiple molecular pathways for fitness recovery of an RNA virus debilitated by operation of Muller's ratchet. J. Mol. Biol. 285 (1999) 495-505
13. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., and Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347 (2002) 975-982
14. Holland J.J., Spindler K., Horodyski F., Grabau E., Nichol S., and VandePol S. Rapid evolution of RNA genomes. Science 215 (1982) 1577-1585
15. Holland J.J., De La Torre J.C., and Steinhauer D.A. RNA virus populations as quasispecies. Curr. Top. Microbiol. Immunol. 176 (1992) 1-20
16. Kobayashi S., Ide T., and Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J. Hepatol. 34 (2001) 584-586
17. Kolykhalov A.A., Mihalik K., Feinstone S.M., and Rice C.M. Hepatitis C virus-encoded enzymatic activities and conserved ARN elements en the 3′ nontranslated-region are essential for virus replication in vivo. J. Virol. 74 (2000) 2046-2051
18. Liu W., Shum C., Martin D.F., Kuppermann B.D., Hall A.J., and Margolis T.P. Prevalence of antiviral drug resistance in untreated patients with cytomegalovirus retinitis. J. Infect. Dis. 182 (2000) 1234-1238
19. Lu L., Pilot-Matias T.J., Stewart K.D., Randolph J.T., Pithawalla R., He W., Huang P.P., Klein L.L., Mo H., and Molla A. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48 (2004) 2260-2266
20. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M.L., Reindollar R., Goodman Z.D., Koury K., Ling M.H., and Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
21. Martell M., Esteban J.I., Quer J., Genesca J., Weiner A., Esteban R., Guardia J., and Gomez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 66 (1992) 3225-3229
22. Mohri H., Singh M.K., Ching W.T., and Ho D.D. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 25-29
23. Najera I., Holguin A., Quinones-Mateu M.E., Munoz-Fernandez M.A., Najera R., Lopez-Galindez C., and Domingo E. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69 (1995) 23-31
24. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., and Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 (1998) 103-107
25. Neyts J. Selective inhibitors of hepatitis C virus replication. Antivir. Res. 71 (2006) 363-371
26. Parris D.S., and Harrington J.E. Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates. Antimicrob. Agents Chemother. 22 (1982) 71-77
27. Quer J., and Esteban J.I. Epidemiology. In: Thomas H.C., Lemon S., and Zuckerman A.J. (Eds). Viral Hepatitis (2005), Blackwell Publishing, Oxford 407-425
28. Quer J., Murillo P., Esteban J.I., Martell M., Esteban R., and Guardia J. Sexual transmission of hepatitis C virus from a patient with chronic disease to his sex partner after removal of an intrauterine device. Sex. Transm. Dis. 30 (2003) 470-471
29. Quer J., Esteban J.I., Cos J., Sauleda S., Ocana L., Martell M., Otero T., Cubero M., Palou E., Murillo P., Esteban R., and Guardia J. Effect of bottlenecking on evolution of the nonstructural protein 3 gene of hepatitis C virus during sexually transmitted acute resolving infection. J. Virol. 79 (2005) 15131-15141
30. Sarrazin C., Kieffer T.L., Bartels D., Hanzelka B., Muh U., Welker M., Wincheringer D., Zhou Y., Chu H.M., Lin C., Weegink C., Reesink H., Zeuzem S., and Kwong A.D. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132 (2007) 1767-1777
31. Steinhauer D.A., and Holland J.J. Rapid evolution of RNA viruses. Annu. Rev. Microbiol. 41 (1987) 409-433
32. Tong X., Chase R., Skelton A., Chen T., Wright-Minogue J., and Malcolm B.A. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antivir. Res. 70 (2006) 28-38
33. Tong X., Guo Z., Wright-Minogue J., Xia E., Prongay A., Madison V., Qiu P., Venkatraman S., Velazquez F., Njoroge F.G., and Malcolm B.A. Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochemistry 45 (2006) 1353-1361
34. Vignuzzi M., Stone J.K., Arnold J.J., Cameron C.E., and Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439 (2006) 344-348
35. Wohnsland A., Hofmann W.P., and Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin. Microbiol. Rev. 20 (2007) 23-38
36. Yi M., Tong X., Skelton A., Chase R., Chen T., Prongay A., Bogen S.L., Saksena A.K., Njoroge F.G., Veselenak R.L., Pyles R.B., Bourne N., Malcolm B.A., and Lemon S.M. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J. Biol. Chem. 281 (2006) 8205-8215